170 related articles for article (PubMed ID: 36374561)
1. Circulating Exosomal PD-L1 at Initial Diagnosis Predicts Outcome and Survival of Patients with Osteosarcoma.
Wang J; Guo W; Wang X; Tang X; Sun X; Ren T
Clin Cancer Res; 2023 Feb; 29(3):659-666. PubMed ID: 36374561
[TBL] [Abstract][Full Text] [Related]
2. Exosomal PD-L1 and N-cadherin predict pulmonary metastasis progression for osteosarcoma patients.
Wang J; Zhang H; Sun X; Wang X; Ren T; Huang Y; Zhang R; Zheng B; Guo W
J Nanobiotechnology; 2020 Oct; 18(1):151. PubMed ID: 33092576
[TBL] [Abstract][Full Text] [Related]
3. Serum exosomal miR-16-5p functions as a tumor inhibitor and a new biomarker for PD-L1 inhibitor-dependent immunotherapy in lung adenocarcinoma by regulating PD-L1 expression.
Chen HL; Luo YP; Lin MW; Peng XX; Liu ML; Wang YC; Li SJ; Yang DH; Yang ZX
Cancer Med; 2022 Jul; 11(13):2627-2643. PubMed ID: 35347894
[TBL] [Abstract][Full Text] [Related]
4. Serum-derived exosomal PD-L1 expression to predict anti-PD-1 response and in patients with non-small cell lung cancer.
Shimada Y; Matsubayashi J; Kudo Y; Maehara S; Takeuchi S; Hagiwara M; Kakihana M; Ohira T; Nagao T; Ikeda N
Sci Rep; 2021 Apr; 11(1):7830. PubMed ID: 33837261
[TBL] [Abstract][Full Text] [Related]
5. Exosomal PD-L1 Retains Immunosuppressive Activity and is Associated with Gastric Cancer Prognosis.
Fan Y; Che X; Qu J; Hou K; Wen T; Li Z; Li C; Wang S; Xu L; Liu Y; Qu X
Ann Surg Oncol; 2019 Oct; 26(11):3745-3755. PubMed ID: 31087180
[TBL] [Abstract][Full Text] [Related]
6. Circulating Plasma Exosomal PD-L1 Predicts Prognosis of Head and Neck Squamous Cell Carcinoma After Radiation Therapy.
Tamari K; Minami K; Tatekawa S; Seo Y; Fukusumi T; Tanaka H; Suzuki M; Eguchi H; Takenaka Y; Hirata T; Hayashi K; Isohashi F; Shimizu S; Koizumi M; Inohara H; Ogawa K
Adv Radiat Oncol; 2024 Feb; 9(2):101353. PubMed ID: 38405303
[TBL] [Abstract][Full Text] [Related]
7. Circulating exosomal immuno-oncological checkpoints and cytokines are potential biomarkers to monitor tumor response to anti-PD-1/PD-L1 therapy in non-small cell lung cancer patients.
Akbar S; Raza A; Mohsin R; Kanbour A; Qadri S; Parray A; Zar Gul AR; Philip A; Vijayakumar S; Merhi M; Hydrose S; Inchakalody VP; Al-Abdulla R; Abualainin W; Sirriya SA; Al-Bozom I; Uddin S; Khan OM; Mohamed Ibrahim MI; Al Homsi U; Dermime S
Front Immunol; 2022; 13():1097117. PubMed ID: 36741391
[TBL] [Abstract][Full Text] [Related]
8. Tumor-derived exosomal PD-L1 in progression of cancer and immunotherapy.
Rasihashemi SZ; Rezazadeh Gavgani E; Majidazar R; Seraji P; Oladghaffari M; Kazemi T; Lotfinejad P
J Cell Physiol; 2022 Mar; 237(3):1648-1660. PubMed ID: 34825383
[TBL] [Abstract][Full Text] [Related]
9. Tracking the evolution of circulating exosomal-PD-L1 to monitor melanoma patients.
Cordonnier M; Nardin C; Chanteloup G; Derangere V; Algros MP; Arnould L; Garrido C; Aubin F; Gobbo J
J Extracell Vesicles; 2020; 9(1):1710899. PubMed ID: 32002173
[TBL] [Abstract][Full Text] [Related]
10. Homogeneous, Low-volume, Efficient, and Sensitive Quantitation of Circulating Exosomal PD-L1 for Cancer Diagnosis and Immunotherapy Response Prediction.
Huang M; Yang J; Wang T; Song J; Xia J; Wu L; Wang W; Wu Q; Zhu Z; Song Y; Yang C
Angew Chem Int Ed Engl; 2020 Mar; 59(12):4800-4805. PubMed ID: 31912940
[TBL] [Abstract][Full Text] [Related]
11. Comparative analysis of the levels of soluble forms of receptor and ligand of the immunity control point PD-1/PD-L1 in the blood serum of patients with typical bone osteosarcoma and chondrosarcoma.
Kushlinskii NE; Alferov AA; Boulytcheva IV; Timofeev YS; Korotkova EA; Khvan OT; Kuzmin YB; Kuznetsov IN; Bondarev AV; Shchupak MY; Sokolov NY; Efimova MM; Gershtein ES; Sushentsov EA; Aliev MD; Musaev ER
Klin Lab Diagn; 2020 Dec; 65(11):669-675. PubMed ID: 33301655
[TBL] [Abstract][Full Text] [Related]
12. Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer.
Hisakane K; Seike M; Sugano T; Matsuda K; Kashiwada T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Gemma A
Gene; 2023 Mar; 857():147177. PubMed ID: 36623674
[TBL] [Abstract][Full Text] [Related]
13. Correlation of plasma exosomal microRNAs with the efficacy of immunotherapy in
Peng XX; Yu R; Wu X; Wu SY; Pi C; Chen ZH; Zhang XC; Gao CY; Shao YW; Liu L; Wu YL; Zhou Q
J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31959728
[TBL] [Abstract][Full Text] [Related]
14. Homogeneous, Simple, and Direct Analysis of Exosomal PD-L1 via Aptamer-Bivalent-Cholesterol-Anchor Assembly of DNAzyme (ABCzyme) for Tumor Immunotherapy.
Hao J; Wang J; Dong Y; Yang J; Wang Z; Zhao X; Zeng T; Zhao X; Liang H; Li J
Anal Chem; 2023 May; 95(17):6854-6862. PubMed ID: 37027485
[TBL] [Abstract][Full Text] [Related]
15. Prognostic Significance of Programmed Death Ligand 1 Expression and Tumor-Infiltrating Lymphocytes in Axial Osteosarcoma.
Liu P; Xiao Q; Zhou B; Dai Z; Kang Y
World Neurosurg; 2019 Sep; 129():e240-e254. PubMed ID: 31128313
[TBL] [Abstract][Full Text] [Related]
16. Isolation of circulating exosomes and identification of exosomal PD-L1 for predicting immunotherapy response.
Zhang J; Zhu Y; Guan M; Liu Y; Lv M; Zhang C; Zhang H; Zhang Z
Nanoscale; 2022 Jun; 14(25):8995-9003. PubMed ID: 35700522
[TBL] [Abstract][Full Text] [Related]
17. Clinical Implications of Exosomal PD-L1 in Cancer Immunotherapy.
Ayala-Mar S; Donoso-Quezada J; González-Valdez J
J Immunol Res; 2021; 2021():8839978. PubMed ID: 33628854
[TBL] [Abstract][Full Text] [Related]
18. Clinical significance of circulating exosomal PD-L1 and soluble PD-L1 in extranodal NK/T-cell lymphoma, nasal-type.
Li JW; Wei P; Guo Y; Shi D; Yu BH; Su YF; Li XQ; Zhou XY
Am J Cancer Res; 2020; 10(12):4498-4512. PubMed ID: 33415014
[TBL] [Abstract][Full Text] [Related]
19. Clinical significance of PD-L1 expression in serum-derived exosomes in NSCLC patients.
Li C; Li C; Zhi C; Liang W; Wang X; Chen X; Lv T; Shen Q; Song Y; Lin D; Liu H
J Transl Med; 2019 Oct; 17(1):355. PubMed ID: 31665020
[TBL] [Abstract][Full Text] [Related]
20. Apatinib inhibits migration and invasion as well as PD-L1 expression in osteosarcoma by targeting STAT3.
Zheng B; Ren T; Huang Y; Guo W
Biochem Biophys Res Commun; 2018 Jan; 495(2):1695-1701. PubMed ID: 29225166
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]